Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, Franck Morschhauser, Kim Linton, Huiqiang Huang, Faith Galderisi, Syed Quadri, Lingmin Zeng, Daniela Hoehn, John F. Seymour

Blood (2023) 142 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2023-180092

Published: 2023

Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada

Blood (2023) 142 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2023-180935

Published: 2023

Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat

Blood (2022) 140 (Supplement 1): 850–851.

https://doi.org/10.1182/blood-2022-158298

Published: 2022

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Peter M. Voorhees, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J. Costa, MD PhD, Yana Lutska, PharmD, Padma Bobba, Daniela Hoehn, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137105

Published: 2020

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J Costa, MD PhD, Yana Lutska, PharmD, Daniela Hoehn, MDPhD, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 151.

https://doi.org/10.1182/blood-2018-151

Published: 2018

Journal Articles

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Murali Sundaram, MBA, PhD, Marie-Hélène Lafeuille, MA, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 5600.

https://doi.org/10.1182/blood.V130.Suppl_1.5600.5600

Published: 2017

Journal Articles

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Marie-Hélène Lafeuille, MA, Murali Sundaram, MBA, PhD, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 4714.

https://doi.org/10.1182/blood.V130.Suppl_1.4714.4714

Published: 2017

Journal Articles

Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories

Abdullah Mahmood Ali, PhD, Yumin Huang, Ronald F Pinheiro, MD, Fumin Xue, PhD, Jingping Hu, PhD, Nicholas Iverson, BS, Daniela Hoehn, MDPhD, Diego Coutinho, BS, Joseph Lane, MD, Christopher D. Hillyer, MD, Naomi Galili, PhD, Joseph G. Jurcic, MD, Mohandas Narla, DSc, Xiuli An, MD PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 4244.

https://doi.org/10.1182/blood.V130.Suppl_1.4244.4244

Published: 2017

Journal Articles

Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients

Abdullah Mahmood Ali, PhD, Yumin Huang, Diego Coutinho, BS, Brian Chernak, BA, Etienne De Clara, PhD, Daniela Hoehn, MDPhD, Joseph G. Jurcic, MD, Mohandas Narla, DSc, Xiuli An, MD PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 2952.

https://doi.org/10.1182/blood.V130.Suppl_1.2952.2952

Published: 2017

Journal Articles

Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene

Blood (2016) 128 (8): 1101–1111.

https://doi.org/10.1182/blood-2016-03-703819

Published: 2016

Includes: Supplemental data

Journal Articles

The Effect of High LET Space Radiation on the Human Hematopoietic System: Preliminary Results from the First In Vivo Model

Daniela Hoehn, MDPhD, George Vlad, PhD, Geo Serban, PhD, Young Erik, PhD, Lubomir Smilenov, PhD

Blood (2015) 126 (23): 5416.

https://doi.org/10.1182/blood.V126.23.5416.5416

Published: 2015

Journal Articles

The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)

Dejan Radeski, MBBS,FRACP,FRCPA, Daniela Hoehn, MD PhD, Francesca Montanari, MD, Bachir Alobeid, MD, Yuan Zhang, MS MA, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Owen A. O'Connor, MD PhD, Govind Bhagat, MD

Blood (2014) 124 (21): 4449.

https://doi.org/10.1182/blood.V124.21.4449.4449

Published: 2014

Journal Articles

Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study

Mihai Merzianu, MD, Richard Cheney, MD, Adrienne Groman, MS, George Deeb, MD, Gregory Wilding, PhD, Claudiu Cotta, MD, Ramila Amre, MD, Manjula Balasubramanian, MD, Guilherme Brandao, MD, Russell K. Brynes, MD, Sindhu Cherian, MD, Elizabeth Courville, MD, David Czuchlewski, MD, Guang Fan, MD PhD, David Grier, MD, Daniela Hoehn, MD PhD, Robert E Hutchison, MD, Kedar V. Inamdar, MD PhD, Ridas Juskevicius, MD, Prabhjot Kaur, MD, John Lazarchick, MD, Michael R Lewis, MD, Rodney R. Miles, MD PhD, Jerome B. Myers, MD PhD, Michel Nasr, MD, Hina Naushad, MD, Horatiu Olteanu, MD PhD, Attilio Orazi, MD, Vishnu VB Reddy, MD, Valentin G Robu, MD, Gratian Salaru, MD, Julie Teruya-Feldstein, MD, Neerja Vajpayee, MD, Jeffrey Vos, MD, Ling Zhang, MD, Shanxing Zhang, MD PhD, Ashley V Sedelmeyer, MHA, Vivian Arguello, MD, Le Aye, DO, Sharon Barouk, MA, Elisa F Brega, MD PhD, Richie Carpenter, BS, James E. Coad, MD, Alana DiPonio, MT, Fernandez Garcia, MS, MD, John Grantham, BS, Sinisa Ivelja, MD, Robert McKenna, MD, Kieran Sultan, MD, Matthew B Thomsen, MPH, Jie Xu, MD PhD, LoAnn Peterson, MD, Vishala T. Neppalli, MD

Blood (2014) 124 (21): 1316.

https://doi.org/10.1182/blood.V124.21.1316.1316

Published: 2014

Journal Articles

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kantarjian Hagop, MD, Deborah Thomas, MD, Guillermo Garcia-Manero, MD, Daniela Hoehn, MD, PhD, Rebecca Garris, BSc, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD

Blood (2013) 122 (21): 2664.

https://doi.org/10.1182/blood.V122.21.2664.2664

Published: 2013

Journal Articles

Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux)

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Jing Ning, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Daniela Hoehn, MD, PhD, Jeffrey Bryan, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4050.

https://doi.org/10.1182/blood.V122.21.4050.4050

Published: 2013

Journal Articles

Next-Generation High Throughput Sequencing Analysis In The Search Of Infectious Pathogens In Suspect Lymphoproliferations

Daniela Hoehn, MD, PhD, Jordan M. Schecter, MD, David Hirschberg, MD, Cadhla Firth, Craig R Street, Bachir Alobeid, MD, Ian W Lipkin, MD, Govind Bhagat, MD

Blood (2013) 122 (21): 3019.

https://doi.org/10.1182/blood.V122.21.3019.3019

Published: 2013

Journal Articles

Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)

Elias Jabbour, MD, Hagop M Kantarjian, MD, Wei Qiao, Paolo Strati, MD, Navira F Khan, Jorge E. Cortes, MD, Daniela Hoehn, MD, PhD, Jianhua Hu, Susan Obrien, MD, Jeffrey Bryan, Hillary Prescott, Courtney D. DiNardo, MD, Naval Daver, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2801.

https://doi.org/10.1182/blood.V122.21.2801.2801

Published: 2013

Journal Articles

Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study

Jordan M. Schecter, MD, Daniela Hoehn, MD, PhD, Philip Imus, MD, Eleonora Alma, BS, Suzanne Lentzsch, MD, PhD, Bachir Alobeid, MD, Manuela Orjuela, MD, ScM, Owen A. O'Connor, MD, PhD, Govind Bhagat, MD

Blood (2013) 122 (21): 4333.

https://doi.org/10.1182/blood.V122.21.4333.4333

Published: 2013

NARROW

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories

Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients

Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene

The Effect of High LET Space Radiation on the Human Hematopoietic System: Preliminary Results from the First In Vivo Model

The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)

Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux)

Next-Generation High Throughput Sequencing Analysis In The Search Of Infectious Pathogens In Suspect Lymphoproliferations

Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)

Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only